Amphastar Pharmaceuticals Inc Revenue Growth Rates (AMPH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Amphastar Pharmaceuticals Inc   (NASDAQ: AMPH)
 

AMPH's Revenue Growth by Quarter and Year

Amphastar Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AMPH Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 183.90
1st Quarter March 171.17
FY 355.07

AMPHs Annual Revenue
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 719.89 millions
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 731.97 millions
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 644.40 millions
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 498.99 millions
Amphastar Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 437.77 millions




AMPH Revenue second quarter 2026 Y/Y Growth Comment
Amphastar Pharmaceuticals Inc reported Revenue growth of 5.44% year on year in the second quarter 2026, to $ 183.90 millions, this is lower than Amphastar Pharmaceuticals Inc 's recent average Revenue increase of 10.8%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 115 other companies have achieved higher Revenue growth. While Amphastar Pharmaceuticals Inc ' s Revenue increase of 5.44% ranks overall at the positon no. 2192 in the second quarter 2026.


AMPH Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -2.79 % 5.75 % 31.91 %
3rd Quarter September - 0.33 % 5.9 % 50.3 %
2nd Quarter June 5.44 % -4.38 % 25.17 % 18.01 %
1st Quarter March 0.38 % -0.76 % 22.73 % 16.32 %
FY   - -1.9 % 13.87 % -

Financial Statements
Amphastar Pharmaceuticals Inc 's second quarter 2026 Revenue $ 183.90 millions AMPH's Income Statement
Amphastar Pharmaceuticals Inc 's second quarter 2025 Revenue $ 174.41 millions Quarterly AMPH's Income Statement


AMPH Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -4.55 % -1.49 % -1.36 %
3rd Quarter September - 9.99 % 4.84 % 23.92 %
2nd Quarter June 7.44 % 2.28 % 6.14 % 4.06 %
1st Quarter March -6.52 % -9.47 % -3.52 % 3.7 %
FY (Year on Year)   - -1.9 % 13.87 % -


Back to AMPH Growth rate Comparisons >> Back to AMPH Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #116
Healthcare Sector #322
Overall #2192

Revenue Y/Y Growth Statistics
High Average Low
50.3 % 10.8 % -21.63 %
(Jun 30 2024)   (Sep 30 2017)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #116
Healthcare Sector #322
Overall #2192
Revenue Y/Y Growth Statistics
High Average Low
50.3 % 10.8 % -21.63 %
(Jun 30 2024)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Amphastar Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
23.91 % 2.88 % -22.81 %
(Sep 30 2023)  


AMPH's II. Quarter Q/Q Revenue Comment
Amphastar Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 7.44%, to $ 183.90 millions, from $171.17 millions in the first quarter.
AMPH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Amphastar Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 960.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #144
Overall #960
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #144
Overall #960
Revenue Q/Q Growth Statistics
High Average Low
23.91 % 2.88 % -22.81 %
(Sep 30 2023)  


AMPH's II. Quarter Q/Q Revenue Comment
Amphastar Pharmaceuticals Inc achieved in the II. Quarter 2026 above company average sequential Revenue increase of 7.44%, to $ 183.90 millions, from $171.17 millions in the first quarter.
AMPH is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Amphastar Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 960.


Amphastar Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 730.02 $ 720.53 $ 719.89 $ 725.14 $ 724.52
Y / Y Revenue Growth (TTM) 0.76 % -1.63 % -1.9 % 0.22 % 1.63 %
Year on Year Revenue Growth Overall Ranking # 2448 # 1078 # 298 # 221 # 191
Seqeuential Revenue Change (TTM) 1.32 % 0.09 % -0.72 % 0.09 % -1.09 %
Seq. Revenue Growth (TTM) Overall Ranking # 2712 # 2427 # 1371 # 1473 # 1088


Cumulative Revenue growth Comment
Although Amphastar Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 11.39% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 0.76% year on year, from -1.63% in Mar 31 2026.

In the Healthcare sector 353 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1078 to 2448.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 354
Overall # 2448

Revenue TTM Y/Y Growth Statistics
High Average Low
31.8 %
 11.39 %
-9.39 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 388
S&P 500 # 2712
Cumulative Revenue growth Comment
Although Amphastar Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 11.39% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 0.76% year on year, from -1.63% in Mar 31 2026.

In the Healthcare sector 353 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1078 to 2448.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 123
Healthcare Sector # 354
Overall # 2448

Revenue TTM Y/Y Growth Statistics
High Average Low
31.8 %
11.39 %
-9.39 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 123
Sector # 388
S&P 500 # 2712




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
AMPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Sotera Health Company9.45%$ 9.452 millions
Illumina Inc 9.44%$ 9.443 millions
Stryker Corp9.42%$ 9.415 millions
International Stem Cell Corporation9.32%$ 9.318 millions
Cytosorbents Corporation9.29%$ 9.292 millions
Resmed Inc 9.22%$ 9.222 millions
Fate Therapeutics Inc 9.18%$ 9.177 millions
Bausch and Lomb Corp9.08%$ 9.077 millions
Pacs Group Inc 9.07%$ 9.071 millions
Electromed Inc 8.97%$ 8.968 millions
National Healthcare Corp8.83%$ 8.833 millions
Chemed Corporation8.80%$ 8.800 millions
Tactile Systems Technology Inc 8.76%$ 8.763 millions
Gyre Therapeutics Inc 8.72%$ 8.718 millions
P3 Health Partners Inc 8.60%$ 8.599 millions
Maravai Lifesciences Holdings Inc 8.53%$ 8.534 millions
U S Physical Therapy Inc8.47%$ 8.470 millions
Ocugen Inc 8.38%$ 8.376 millions
Baxter International Inc 8.36%$ 8.363 millions
Carlisle Companies Incorporated8.33%$ 8.334 millions
Universal Health Services Inc 8.27%$ 8.268 millions
Addus Homecare Corp8.18%$ 8.181 millions
Puma Biotechnology Inc 7.75%$ 7.754 millions
Cryoport inc 7.74%$ 7.737 millions
Schrodinger Inc 7.54%$ 7.542 millions
Boston Scientific Corporation7.53%$ 7.528 millions
Agilon Health Inc 7.15%$ 7.151 millions
Tenet Healthcare Corp6.77%$ 6.773 millions
Henry Schein Inc 6.73%$ 6.728 millions
Collegium Pharmaceutical Inc 6.67%$ 6.668 millions


About Amphastar Pharmaceuticals Inc Revenue Growth Rates (AMPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Amphastar Pharmaceuticals Inc (CIK 1297184).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001297184-26-000047
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Amphastar Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.